The VIEW 2 Study (VEGF Trap-Eye Investigation of Efficacy and Safety in Wet AMD): 52-Week Results

Yuichiro Ogura

Purpose: To evaluate the efficacy and safety of VEGF Trap-Eye versus ranibizumab in preventing moderate vision loss in patients with choroidal neovascularization secondary to age-related macular degeneration (AMD).

Methods: In this double-masked, non-inferiority, Phase 3 study conducted in South America, Europe, and Asia-Pacific, patients were randomized to VEGF Trap-Eye 0.5 mg every 4 weeks, 2 mg every 4 weeks, 2 mg every 8 weeks following 3 monthly loading doses, or ranibizumab 0.5 mg every 4 weeks. The primary outcome is the proportion of patients avoiding moderate vision loss (patients losing <15 ETDRS letters) from baseline to week 52. Secondary assessments include the mean change from baseline in BCVA by ETDRS letter score.

Results: 1240 patients were randomized in this study. 52-week data will become available by the end of 2010. Efficacy and safety results will be presented and discussed.

Conclusions: The 52-week results of VIEW 2 will provide important information regarding the relative efficacy and safety of anti-angiogenic treatment options for patients with neovascular AMD.